RecruitingPhase 2NCT06198712
A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
Studying Sickle cell disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Forma Therapeutics, Inc.
- Principal Investigator
- Clinical Transparency (dept. 2834)Novo Nordisk A/S
- Intervention
- Etavopivat(drug)
- Enrollment
- 50 enrolled
- Eligibility
- 12-18 years · All sexes
- Timeline
- 2023 – 2029
Study locations (18)
- The Hospital for Sick Children, Toronto, Ontario, Canada
- Hospices Civils de Lyon, Lyon, France
- APHP - Centre de Référence des Syndromes, Paris, France
- Centre Hospitalier Universitaire de Rouen-Hopital Charles Nicolle, Rouen, France
- KEMRI-Walter-Reed Kericho, Kericho, Kenya
- Kombewa Clinical Research Centre, Kisumu, Kenya
- Ahero Clinical Trials Unit, Kisumu, Kenya
- Kenya Medical Research Institute-Centre for Respiratory Disease Research, Siaya Clinical Research Annexe, Siaya, Kenya
- American University of Beirut Medical center, Beirut, Lebanon
- Hospital Nini, Tripoli, Lebanon
- University of Nigeria Teaching Hospital (UNTH), Ituku-Ozalla, Enugu State, Nigeria
- Lagos University Teaching Hospital, Lagos, Lagos, Nigeria
- Aminu Kano Teaching Hospital (AKTH), Tarauni, Nigeria
- Hacettepe University pediatric hematology, Ankara, Turkey (Türkiye)
- Acıbadem Adana Hastanesi, Seyhan, Turkey (Türkiye)
- +3 more locations on ClinicalTrials.gov
Collaborators
Novo Nordisk A/S
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06198712 on ClinicalTrials.govOther trials for Sickle cell disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT06979492Prophylactic Transfusion In Pregnant in Women With Sickle Cell DiseaseEmory University
- RECRUITINGNCT07392216Functional Ovarian Reserve in Sickle Cell DiseaseSt. Jude Children's Research Hospital
- RECRUITINGNANCT07246265Morphine Clearance and Glomerular Filtration in Sickle Cell Patients in Crisis in Intensive CareUniversity Hospital, Tours
- ENROLLING BY INVITATIONPHASE2NCT07401823Open-Label Extension Study to Pioneer Study 6058-SCD-101Fulcrum Therapeutics
- RECRUITINGPHASE1, PHASE2NCT07432867Efficacy Safety Study of Gene Therapy for Sickle Cell DiseaseSCD Using Autologous CD34+ Cells Transduced ex Vivo, Carrying a Corrected Globin Gene and a Silencing RNA.Assistance Publique - Hôpitaux de Paris
- RECRUITINGNANCT07222475Writing Relaxing Beats in Adolescents Who Have Sickle Cell DiseaseMayo Clinic
- RECRUITINGPHASE2NCT07224360Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)CSL Behring
- RECRUITINGPHASE3NCT07247188Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell DiseaseSanofi